8-K/A: LeonaBio Secures Lasofoxifene Rights, $236M for Breast Cancer Drug

LeonaBio, Inc. (formerly Athira Pharma) has acquired exclusive global rights to lasofoxifene, a Phase 3 metastatic breast cancer candidate, backed by up to $236 million in financing.

Summary

• LeonaBio, Inc. (formerly Athira Pharma, Inc.) has acquired exclusive global development and commercialization rights to lasofoxifene, a selective estrogen receptor modulator (SERM) for metastatic breast cancer, from Sermonix Pharmaceuticals, Inc. (excluding Asia and certain Middle East countries).
• The acquisition is supported by an upfront private placement financing of $90 million, with warrants providing up to an additional $146 million upon exercise, totaling up to $236 million.
• The financing is co-led by Commodore Capital, Perceptive Advisors, and TCGX, with participation from several other investors, and is expected to provide capital runway into 2028.
• Lasofoxifene is currently in the ongoing Phase 3 ELAINE-3 clinical trial (NCT05696626), which is over 50% enrolled, with topline data expected in the second half of 2027.
• The ELAINE-3 study protocol is being amended to increase the sample size from 500 to up to 600 participants to ensure sufficient disease progression events, with enrollment expected to complete in Q4 2026.
• LeonaBio expects to incur approximately $45 million in cash expenditures for the ELAINE-3 Study in 2026 and $30 million in 2027, significantly increasing the pace and intensity compared to Sermonix's prior efforts.
• As part of the transaction, LeonaBio will issue a pre-funded warrant to Sermonix and is obligated to make up to $100 million in milestone payments and tiered royalties on net sales.
• LeonaBio has also assumed $16,815,728.00 in Sermonix liabilities and provided initial advances of $311,531.43, with monthly advances of $75,000 to follow, all creditable against future payments.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive strategic move, securing a promising late-stage asset in a significant market with substantial financing, indicating strong investor confidence and a clear path for development.

Positives

• Secured exclusive global rights to lasofoxifene, a promising Phase 3 asset for metastatic breast cancer, addressing a high unmet medical need.
• Up to $236 million in financing provides significant capital, extending the company's runway into 2028, supporting development through topline data readout and key regulatory milestones.
• Lasofoxifene demonstrated compelling Phase 2 clinical data, including improved progression-free survival (5.6 vs. 3.7 months in ELAINE-1) and high objective response rates (56% in ELAINE-2 combination).
• The drug's tissue-selective SERM profile offers potential tolerability, bone protection, and quality of life benefits, positioning it as a potential preferred endocrine therapy.
• The target market for ESR1-mutated metastatic breast cancer is substantial and growing, with the global market projected to reach $41.7 billion by 2030.
• Increased investment and pace in the ELAINE-3 study, including expanded CRO activities and sample size, aim to bolster development efforts and ensure robust trial outcomes.

Negatives

• No explicit negatives are highlighted in the filing, which focuses on the positive aspects of the acquisition and financing.

Risks

• The data from preclinical and clinical trials may not support the safety, efficacy, and tolerability of drug candidates.
• Development of drug candidates may cease or be delayed.
• Regulatory authorities could object to protocols, amendments, and other submissions.
• Future potential regulatory milestones for drug candidates may be insufficient to support regulatory submissions or approval.
• There is a risk that trials are not sufficiently powered to meet planned endpoints.
• The company may not be able to recruit sufficient patients for its clinical trials.
• Possible negative interactions of drug candidates with other treatments.
• FDA regulatory delays and uncertainty, including new policies, changes in leadership of federal agencies, staff layoffs, budget cuts, and changes in drug pricing controls.
• Assumptions regarding financial condition and sufficiency of cash, cash equivalents, and investments to fund planned operations may be incorrect.
• Adverse conditions in the general domestic and global economic markets, including as a result of tariffs.
• Impact of competition and new or changing laws and regulations.

Future Outlook

LeonaBio expects to complete enrollment for the ELAINE-3 Study in the fourth quarter of 2026 and release topline data in the second half of 2027. The company plans to initiate a Phase 2 clinical trial of ATH-1105 in ALS patients in early 2026. The secured financing is anticipated to support lasofoxifene development through its topline data readout and key regulatory milestones, providing capital runway into 2028. If approved, lasofoxifene has the potential to become a new standard of care for ESR1-mutated metastatic breast cancer patients.

Management Comments

• Mark Litton, Ph.D., President and CEO of Athira: 'Today marks a defining moment for our company. This agreement for the rights to the Phase 3 lasofoxifene program for metastatic breast cancer is a significant step in building a pipeline with the potential to change lives and create enduring value.'
• Mark Litton, Ph.D., President and CEO of Athira: 'This program provides a near-term opportunity to generate pivotal data necessary for the approval of lasofoxifene and to establish it as the new standard of care to treat ESR1-mutant breast cancer in patients who have progressed on aromatase inhibitors and prior CDK4/6 inhibitors.'
• David Portman, M.D., Chief Executive Officer of Sermonix: 'We believe lasofoxifene has the potential to be the preferred endocrine therapy for metastatic breast cancer patients given its tissue-selective SERM profile may allow for the preservation of estrogen function in non-breast tissue, which provides tolerability and potential bone protection and quality of life benefits.'
• Cariad Chester, Managing Partner at TCGX: 'With its differentiated profile, lasofoxifene has the potential to become the endocrine therapy of choice for the approximately 40% of breast cancer patients who develop ESR1 mutations and have progressed on aromatase inhibitors and prior CDK4/6 inhibitors.'
• Joseph Edelman, Founder and CEO of Perceptive Advisors: 'The scientific and clinical data supporting lasofoxifene are compelling, and we are confident in Athira’s leadership to drive the Company’s next chapter with clarity, urgency and excellence.'

Industry Context

StockSavvy.ai notes that this acquisition positions LeonaBio to enter the rapidly expanding metastatic breast cancer market, projected to grow from $17.1 billion in 2021 to $41.7 billion by 2030. The focus on ESR1-mutated, ER+, HER2-negative patients addresses a specific, high-need segment where current treatment options are limited after progression on standard therapies like aromatase inhibitors and CDK4/6 inhibitors. The investment by blue-chip investors signals confidence in lasofoxifene's potential to differentiate itself among SERMs and other endocrine therapies, particularly given its tissue-selective profile and promising Phase 2 data. This move diversifies LeonaBio's pipeline beyond neurodegenerative diseases, indicating a strategic expansion into oncology.

Comparison to Industry Standards

• ELAINE-1 trial showed lasofoxifene improved median progression-free survival (PFS) to 5.6 months compared to 3.7 months for fulvestrant, a commonly used endocrine therapy, in a randomized setting.
• ELAINE-2 trial demonstrated a median PFS of approximately 13 months for lasofoxifene in combination with abemaciclib in heavily pretreated secondand third-line ESR1-mutated metastatic breast cancer patients, alongside an objective response rate (ORR) of 56% and a clinical benefit rate (CBR) of 65.5%. These results suggest a strong efficacy profile in a challenging patient population.
• The company aims to establish lasofoxifene as the new standard of care for ESR1-mutant breast cancer patients who have progressed on aromatase inhibitors and prior CDK4/6 inhibitors, indicating a high bar for efficacy and safety compared to existing or emerging treatments in this specific niche.

Related Party Transactions

• Ligand Pharmaceuticals participated in the private placement financing, and separate license agreements (Ligand-Sermonix Agreement and Ligand-Athira Agreement) were entered into with Ligand, indicating an ongoing relationship.

Stakeholder Impact

• **Shareholders:** Potential for significant value creation if lasofoxifene successfully navigates clinical trials and gains regulatory approval, given the large market opportunity. Dilution from the private placement is a factor, but offset by substantial capital infusion.
• **Patients:** Offers a new, potentially more effective and tolerable treatment option for ESR1-mutated metastatic breast cancer, a population with limited alternatives.
• **Employees:** Strategic expansion into oncology could lead to new opportunities and growth within the company.
• **Sermonix Pharmaceuticals:** Receives upfront warrants, potential milestone payments up to $100 million, and royalties, validating their development efforts and providing financial upside.
• **Investors (in private placement):** Gain exposure to a late-stage oncology asset with significant upside potential, backed by a clear development strategy and experienced management.

Next Steps

• Complete enrollment of the ELAINE-3 Study in the fourth quarter of 2026.
• Release topline data from the ELAINE-3 Study in the second half of 2027.
• Initiate a Phase 2 clinical trial of ATH-1105 in ALS patients in early 2026.
• File registration statements with the SEC covering the resale of shares and warrants from the private placement.

Key Dates

Recommendation

The acquisition of a late-stage, de-risked asset like lasofoxifene, coupled with substantial financing from reputable institutional investors, significantly enhances LeonaBio's pipeline and market potential. The compelling Phase 2 data and the large, growing market for ESR1-mutated metastatic breast cancer suggest a high probability of success and significant revenue generation if approved. The capital runway into 2028 provides stability for key development milestones. This strategic move diversifies the company's portfolio and positions it for substantial growth, making it a strong buy for long-term investors.

Keywords

Lasofoxifene, Metastatic Breast Cancer, SERM, ESR1-mutated, ELAINE-3, Clinical Trial, Biopharmaceutical, Oncology, Drug Development, Private Placement, Financing, Athira Pharma, LeonaBio, Sermonix Pharmaceuticals, ATH-1105, ALS